Study of Pembrolizumab With or Without Platinumb-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (KEYNOTE-361)

The purpose of this study is to determine the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy versus chemotherapy alone in participants with advanced or metastatic urothelial carcinoma (bladder cancer).

Primary Sponsor:
Merck

Prinicipal Investigator:
Jianqing Lin, M.D./Medicine; Division of Hematology/Oncology

Contact Phone:
202-741-2981

Are you interested in more information on this clinical trial?

First Name *
Last Name *
Email *
Street Address *
City *
State *
Zip Code *
Phone Number 
     
Verification Code *

Please type what you see (all uppercase):